Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Bleeding Disorders

19 April 2017 Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment

Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA® [lonoctocog alfa].

> Read More
10 April 2017 Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World

CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).

> Read More
09 January 2017 AFSTYLA®, for Haemophilia A, Receives European Commission Approval

Global biotherapeutics leader CSL Behring announced today that the European Commission has granted marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for children and adults with haemophilia A.

> Read More
14 December 2016 Health Canada Approves CSL Behring’s AFSTYLA for the Treatment of Hemophilia A

Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.

> Read More
03 December 2016 CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.

> Read More
Page 1 of 4 Next | Last

Share
LinkedIn Twitter Facebook Google+